Status:
COMPLETED
Cardiovascular Risk Assessment in Patients Treated With Caduet
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Compare the reduction in Framingham's predicted 10-year risk of a coronary event (6) in patients with hypertension and at least three other cardiovascular risk factors (including diabetic patients) se...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or over, 2.Patient with hypertension and at least three other CV risk factors, 3.Hypertension, treated or not, but not at the currently recommended goals (140/90 mmHg for most patients, 130/80 mmHg for patients with diabetes or nephropathy). In case of treated hypertension, patients should be on their current treatment for at least 4 weeks before randomisation,
Exclusion
- 1\. Patient with a history of coronary heart disease, 2.Patients with a history of familial hypercholesterolemia, 3.Patient with malignant HTN, 4.Non-essential hypertension, 5.Known hypersensitivity to dihydropyridines, 6.Patients already receiving a dihydropyridine, 7.Known hypersensitivity to HMG-CoA-reductase inhibitors, 8.Patients currently receiving or who has received a HMG-CoA-reductase within the 3 months prior to selection, 9.Patients currently receiving or who has received a fibric acid, resins, ezetimibe, nicotinic acid and all other drug which is known to affect lipid levels, within 6 weeks prior to selection,
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
1442 Patients enrolled
Trial Details
Trial ID
NCT00297973
Start Date
February 1 2006
End Date
April 1 2007
Last Update
January 27 2021
Active Locations (384)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Abbeville, France, 80100
2
Pfizer Investigational Site
Aire-sur-la-Lys, France, 62120
3
Pfizer Investigational Site
Aix-les-Bains, France, 73100
4
Pfizer Investigational Site
Alençon, France, 61000